Zydus Lifesciences Ltd closed at ₹1,195.00 on the BSE on Friday, shedding ₹1.40 or 0.12% in subdued trading even as its clinical pipeline scored a critical win. The drugmaker's wholly owned arm, Zydus Therapeutics, posted Phase 2b trial data showing its investigational compound saroglitazar magnesium cleared metabolic dysfunction-associated steatohepatitis (MASH) without aggravating liver scarring. The headline numbers delivered a decisive separation from standard control groups.
The trial cleared its primary hurdle. At the 4 mg once-daily dosage, 39.1% of patients achieved resolution of steatohepatitis without worsening fibrosis after 52 weeks. The 2 mg cohort posted a 32.4% response. Just 13.7% of placebo recipients matched that bar. That handed the 4 mg arm a net treatment difference of 24.9 percentage points over placebo, while the 2 mg arm registered a 16.5 percentage point delta across 189 biopsy-confirmed adult patients staged at F2 to F3 fibrosis.
| Trial Arm | 52-Week MASH Resolution | Treatment Delta vs Placebo | Fibrosis Improvement (≥1 Stage) |
|---|---|---|---|
| Placebo | 13.7% | — | 24.6% |
| Saroglitazar 2 mg | 32.4% | +16.5 pp | 22.8% |
| Saroglitazar 4 mg | 39.1% | +24.9 pp | 34.8% |
Yet the secondary endpoint told a more nuanced story. The study tracked whether patients improved liver fibrosis by at least one stage without worsening their Non-Alcoholic Fatty Liver Disease Activity Score. Here, the 4 mg dose generated a 34.8% response rate against 24.6% in the placebo cohort—a 10.2 percentage point spread that failed to reach statistical significance. The lower 2 mg dose trailed at 22.8%.
But blood and imaging biomarkers tracked in the background tilted back toward the drug. Non-invasive scores dropped across the board for the 4 mg cohort. The treatment difference for Pro-C3 settled at -9.50 ng/mL, while the AST to Platelet Ratio Index fell -0.35. Parallel drops hit the Fibrosis-4 Index at -0.30 and the ADAPT score at -0.53, confirming metabolic changes under the surface.
Tolerability held steady across the 52-week multi-country trial, which ran across testing sites in the United States, Argentina, and Turkey. Investigators observed no drug-induced liver injury signals. Weight gain—often a vulnerability in metabolic liver compounds—did not emerge.
"Many people with MASH and fibrosis also have type 2 diabetes or obesity, so we need options that address both the liver disease and the metabolic dysfunction that drives it," said Dr. Naga Chalasani, David W. Crabb Professor of Gastroenterology and Hepatology and co-editor-in-chief of HEPATOLOGY. He noted that the trial coupled liver clearance with direct improvements in glycemic and lipid profiles.
Zydus Therapeutics plans to showcase the complete data set during a late-breaking oral presentation at The Liver Meeting 2026, the annual conference of the American Association for the Study of Liver Diseases. Regulators still classify saroglitazar as an investigational product for MASH, leaving the pharmaceutical firm focused on scaling these findings into pivotal, larger-scale Phase 3 trials.